Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04890652 · ClinicalTrials.gov registry record · NA
Digital Interventions to Treat Hazardous Drinking
A NA study of Stress and Hazardous Drinking, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04890652: Completed NA study of Stress and Hazardous Drinking, sponsored by Yale University.
NCT04890652 is a NA study of Stress and Hazardous Drinking that has completed, run by Yale University. The registered enrollment target is 33 participants, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04890652, a NA study of Stress and Hazardous Drinking, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
There has been a significant increase in the prevalence of stress- and alcohol- related disorders during the COVID-19 pandemic. This project aims to conduct a feasibility study to evaluate the preliminary efficacy of a digital intervention designed to reduce stress and alcohol use. Additionally, this study will examine the impact of stress, including COVID-19 related stress, on the risk of alcohol misuse and the outcomes of the intervention in risky social drinkers.
Primary Outcome
The average number of alcoholic beverages consumed per week (drinks per week), as measured by the Timeline Follow Back.
Conditions Studied
Interventions
- BEHAVIORAL Digital intervention
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2023-08-23 |
| Phase | NA |
What the finished NCT04890652 record still lists
NCT04890652 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 786-participant average among 152 other Stress trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Stress appearing as the primary indexed condition, and to 1 intervention - of which Digital intervention is the first listed.
NCT04890652 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04890652 about?
NCT04890652 is a clinical study titled "Digital Interventions to Treat Hazardous Drinking". There has been a significant increase in the prevalence of stress- and alcohol- related disorders during the COVID-19 pandemic. This project aims to conduct a feasibility study to evaluate the preliminary efficacy of a digital intervention designed to reduce stress and alcohol use. Additionally, thi...
What is the current status of trial NCT04890652?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2021-10-13. Estimated completion is 2023-08-23.
What conditions does trial NCT04890652 study?
This clinical trial studies the following conditions: Stress, Hazardous Drinking.
What interventions are being tested in trial NCT04890652?
The interventions under investigation include: Digital intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04890652?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04890652 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stress
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04890652's enrollment target sits among peer trials
33 128th of 152 higher than 25 of 152 other Stress trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stress trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindfulness-Based Intervention With a Supplement for Stress-Related Problems in College Students Across Multiple Sites (4SITE)
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
Student Exercise and Sleep Timing Study - Part 2
RECRUITING · NA
-
Smartphone-based Cognitive Emotion Regulation Training for Unpaid Primary Caregivers of Persons With Alzheimer's Disease
RECRUITING · NA
-
ACT for HIV-Positive Men
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI